News of Note—Sanofi, Dynavax and more


Here is some other vaccine news of note for the week:

> The FDA approved an expanded use for Sanofi's Tdap vaccine Adacel to allow for repeat vaccinations. Release

> Dynavax predicts an "inflection point" in sales for its Heplisav-B vaccine and that the vaccine will be profitable by the end of 2019. Presentation

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

> The Coalition for Epidemic Preparedness Innovations (CEPI) tapped the University of Queensland in a deal worth up to $10.6 million to develop a “molecular clamp” vaccine platform, which enables rapid vaccine production against multiple viral pathogens. Release

> Univercells launched its low-cost vaccine production system, NevoLine, triggering a $4 million grant extension from the Bill & Melinda Gates Foundation to scale up the platform. Release


Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

Ad Environment Matters for Message Receptivity

After the U.K.'s nod for Pfizer's vaccine, NIAID Director Anthony Fauci argues the country’s regulators acted too quickly.